According to a study by Decision Resources, primary care physicians prefer Boehringer Ingelheim’s Spiriva to other first-line COPD treatments, with 44% surveyed saying they would increase their use of the drug in the next few years. That percentage is down from 59% in 2009. Read the company’s press release.
Decision Resources predicts Spiriva will increase market share for COPD
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
